Bringing the fundamentals into focus…
Back to Charles River Laboratories International, Inc.
How Charles River Laboratories International, Inc. stacks up
CRL · against 124 other Healthcare companies of similar size
Valuation
43/ 100
Below the middle of the pack.
Ranked #89 of 125 · scores higher than 27% of peers
Bars: peers in each 10-point band of the valuation score21 peers with a valuation score of 40–49, including CRL · Click a bar to see the companies
Why valuation scores 43?
Weighted metrics compared with all Healthcare companies.A mix: stronger free cash flow yield, but weaker earnings yield than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -1.4% vs peer median 1.5%
- EBITDA yield is close to the peer norm. EBITDA yield: 4.3% vs peer median 4.0%
- more free cash flow for the price paid: stronger than 62% of peers. Free cash flow yield: 2.2% vs peer median 0.0%
Metric by metric
Position: dot = CRL, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | CRL | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 123 reported | -1.4% | 3.0% | 16% | 30% | |
| EBITDA yieldHigher is better · 126 reported | 4.3% | 5.1% | 41% | 50% | |
| Free cash flow yieldHigher is better · 82 reported | 2.2% | 3.1% | 36% | 20% | |
| Book yieldHigher is better · 122 reported | 16.9% | 20.8% | 41% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around CRLScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score